Overview: Venous Thrombosis Risk Analysis Panel
Introduction: The Venous Thrombosis Risk Analysis Panel is a diagnostic tool designed for thrombosis risk assessment using plasma samples. In India, venous thromboembolism (VTE) affects ~100-150 per 100,000 annually (higher in pregnancy, surgery, cancer), with acquired risks (lupus anticoagulant, anticardiolipin) and hyperhomocysteinemia common in low-SES populations due to malnutrition/B12 deficiency. High morbidity from under-testing leading to recurrent DVT/PE or fatal events, limited coagulation labs, delayed anticoagulation. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay for homocysteine, lupus anticoagulant, and anticardiolipin IgG over 3â€"5 days with high accuracy, valuable for identifying treatable risks in unprovoked VTE or pregnancy loss. This diagnostic falls under coagulation screening and targets patients with VTE, stroke, or obstetric complications, addressing accurate detection to guide anticoagulation or folate/B12 supplementation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise thrombotic risk profiling and reducing recurrence. Its plasma-based approach ensures reliable functional/serologic assessment.
Other Names: Ven Thromb Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Thrombosis risk panel standard in VTE workup; in India, expanding in thrombosis clinics.
Purpose: The test assesses 3 parameters including homocysteine to guide thrombosis risk screening, detect acquired/hypercoagulable states, inform anticoagulation.
Test Parameters: 1. Homocysteine, 2. Lupus Anticoagulant, 3. Anticardiolipin IgG.
Pretest Condition: No fasting required; patients should have VTE/obstetric history.
Specimen: 3 mL plasma in NaCit tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve coagulation factors, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on thrombosis, miscarriage.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected risk including recurrence, benefits of screening, and minimal discomfort from sampling.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique and interpret results within 3â€"5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Elevated homocysteine or positive lupus anticoagulant indicates increased risk, necessitating specialist input.
Specialist Consultation: Hematologists should be consulted for management.
Additional Supporting Tests: Factor V Leiden, imaging for VTE confirmation.
Test Limitations: Affected by acute thrombosis; comprehensive approach required.
References: Indian Journal of Hematology 2024, Thrombosis Studies India 2023.
